Related Experiment Video
Updated: Aug 16, 2026
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
Discovery of a selective NLRP3-targeting compound with therapeutic activity in MSU-induced peritonitis and
Yinghua Zhou1, Zhongjin Yang1, Yitao Ou1
1Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, China.
Abstract:
The aberrant activation of the nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is known to contribute to the pathogenesis of various human inflammation-related diseases. However, to date, no small-molecule NLRP3 inhibitor has been used in clinical settings. In this study, we have identified SB-222200 as a novel direct NLRP3 inhibitor through the use of drug affinity responsive target stability assay, cellular thermal shift assay, and surface plasmon resonance analysis. SB-222200 effectively inhibits the activation of the NLRP3 inflammasome in macrophages, while having no impact on the activation of NLRC4 or AIM2 inflammasome. Furthermore, SB-222200 directly binds to the NLRP3 protein, inhibiting NLRP3 inflammasome assembly by blocking the NEK7 - NLRP3 interaction and NLRP3 oligomerization. Importantly, treatment with SB-222200 demonstrates alleviation of NLRP3-dependent inflammatory diseases in mouse models, such as monosodium urate crystal-induced peritonitis and dextran sulfate sodium-induced acute intestinal inflammation. Therefore, SB-222200 holds promise as a lead compound for the development of NLRP3 inhibitors to combat NLRP3-driven disease and serves as a versatile tool for pharmacologically investigating NLRP3 biology.
Insights
SB-222200 is a novel small-molecule inhibitor that directly targets the NLRP3 inflammasome, offering potential for treating inflammation-related diseases. This compound effectively blocks NLRP3 activation and shows promise in preclinical models.
Area of Science:
- Immunology
- Pharmacology
- Molecular Biology
Background:
- Aberrant activation of the NLRP3 inflammasome contributes to various human inflammatory diseases.
- No small-molecule NLRP3 inhibitors are currently approved for clinical use.
Purpose of the Study:
- To identify and characterize novel small-molecule inhibitors of the NLRP3 inflammasome.
- To evaluate the therapeutic potential of identified inhibitors in preclinical models of inflammation.
Main Methods:
- Drug affinity responsive target stability assay
- Cellular thermal shift assay
- Surface plasmon resonance analysis
- In vitro inflammasome activation assays
- Mouse models of inflammatory disease
Main Results:
- SB-222200 identified as a direct NLRP3 inhibitor.
- SB-222200 inhibits NLRP3 inflammasome activation in macrophages without affecting NLRC4 or AIM2.
- SB-222200 binds directly to NLRP3, blocking NEK7-NLRP3 interaction and NLRP3 oligomerization.
- SB-222200 alleviates NLRP3-dependent inflammation in mouse models.
Conclusions:
- SB-222200 is a potent and selective NLRP3 inhibitor.
- SB-222200 demonstrates therapeutic potential for NLRP3-driven inflammatory diseases.
- SB-222200 serves as a valuable tool for studying NLRP3 biology.
